Myriad Genetics (MYGN) Price Target Raised to $35.00 at Leerink Swann

Myriad Genetics (NASDAQ:MYGN) had its target price raised by Leerink Swann from $33.00 to $35.00 in a research report sent to investors on Wednesday morning. Leerink Swann currently has a market perform rating on the stock. Leerink Swann also issued estimates for Myriad Genetics’ Q3 2018 earnings at $0.27 EPS, Q4 2018 earnings at $0.30 EPS, FY2018 earnings at $1.14 EPS, Q1 2019 earnings at $0.29 EPS, Q2 2019 earnings at $0.29 EPS, Q3 2019 earnings at $0.30 EPS, Q4 2019 earnings at $0.33 EPS and FY2019 earnings at $1.20 EPS.

Other research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Myriad Genetics from a hold rating to a buy rating in a report on Friday, November 10th. BTIG Research assumed coverage on shares of Myriad Genetics in a report on Friday, January 5th. They set a buy rating and a $41.00 price objective on the stock. Stephens set a $45.00 price objective on shares of Myriad Genetics and gave the stock a buy rating in a report on Wednesday, January 3rd. Barclays boosted their price objective on shares of Myriad Genetics from $30.00 to $35.00 and gave the stock an equal weight rating in a report on Monday, January 22nd. Finally, Zacks Investment Research downgraded shares of Myriad Genetics from a strong-buy rating to a hold rating in a report on Friday, December 15th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $31.42.

Myriad Genetics (NASDAQ:MYGN) opened at $32.96 on Wednesday. The company has a market cap of $2,302.26, a price-to-earnings ratio of 28.91, a P/E/G ratio of 2.44 and a beta of 0.32. Myriad Genetics has a twelve month low of $15.71 and a twelve month high of $41.57. The company has a quick ratio of 2.06, a current ratio of 2.05 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, February 6th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.24 by $0.07. The firm had revenue of $194.00 million for the quarter, compared to the consensus estimate of $188.72 million. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.26 EPS. analysts expect that Myriad Genetics will post 1.15 earnings per share for the current fiscal year.

In other news, insider Alexander Ford sold 3,031 shares of Myriad Genetics stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Richard M. Marsh sold 13,759 shares of Myriad Genetics stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $36.25, for a total transaction of $498,763.75. Following the sale, the vice president now owns 136,385 shares in the company, valued at $4,943,956.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,064 shares of company stock worth $2,679,097. Insiders own 6.70% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. boosted its position in shares of Myriad Genetics by 1,067.4% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after acquiring an additional 3,010 shares in the last quarter. LS Investment Advisors LLC boosted its position in shares of Myriad Genetics by 88.5% during the 4th quarter. LS Investment Advisors LLC now owns 4,791 shares of the company’s stock valued at $165,000 after acquiring an additional 2,250 shares in the last quarter. Commonwealth Equity Services Inc acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $202,000. Teacher Retirement System of Texas acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $204,000. Finally, Shelton Capital Management acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $238,000.

COPYRIGHT VIOLATION NOTICE: “Myriad Genetics (MYGN) Price Target Raised to $35.00 at Leerink Swann” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://sportsperspectives.com/2018/02/11/myriad-genetics-mygn-price-target-raised-to-35-00-at-leerink-swann.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply